At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 132 target
Drug / intervention
Tirabrutinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma
In Brief
A Phase 3 clinical trial evaluating Tirabrutinib, Rituximab, and 1 other intervention for Relapsed/Refractory Primary Central Nervous System Lymphoma. Currently recruiting, targeting 132 participants across 19 sites.
Signals
Enrolling ahead of pace
Detailed Summary
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsDeciphera Pharmaceuticals, LLC
Timeline
Phase 3Recruiting
20262027202820292030
First PostedAug 2025
Enrollment StartJun 2026
TodayJul 2026
Primary CompletionDec 2027
Study CompletionDec 2029
First PostedAug 5, 2025
Enrollment StartJun 12, 2026
Primary CompletionDec 1, 2027
Study CompletionDec 1, 2029
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11 months agoPrimary completion in 1.4 years
Interventions
Tirabrutinibdrug
Administered orally.
Rituximabdrug
Administered intravenously (IV).
Temozolomidedrug
Administered orally.